Catheter Precision, Inc. · AMEX:VTAK
Catheter Precision — Ra Medical Systems — IPO Roadshow (May 2020)
26 slides from Catheter Precision's IPO roadshow presentation, May 15, 2020
Slide 1: Corporate Presentation
Ra Medical Systems Filed pursuant to Rule 433 under the Securities Act of 1933, as amended Dated May 15, 2020 Registration Statement No. 333-237701 Ra Medical Systems, Inc. NYSE: RMED Corporate Presentation May 15, 2020
Slide 2: Disclaimer
Disclaimer Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of Ra Medical Systems, Inc. (the “Company”) and involve known and unknown risks, uncertainties and othe
Slide 3: Ra Medical Snapshot
Ra Medical Snapshot DABRA—Excimer laser that utilizes disposable catheters for crossing total chronic occlusions (CTOs) and ablating a channel in occlusive peripheral vascular disease. DABRA is used as a tool to treat peripheral artery disease (PAD), a form of peripheral vascular disease. Photoablat
Slide 4: Highlights
Highlights Novel Therapeutic Solution with Positive Clinical Study Results Existing US Reimbursement Structure Time Efficient and Easy-to-Use Solution Cost Benefits to Outpatient-Based Catheterization Laboratories $1.1B Targeted Global Annual TAM; >17M PAD Sufferers in the US Single-Use Catheters Hi
Slide 5: Peripheral Artery Disease
Peripheral Artery Disease Disease Overview Atherosclerosis of the lower extremities—most commonly in the legs Smoking, genetic predisposition, diabetes, age and obesity may increase risk Characterized by reduced blood flow to surrounding tissue If untreated can cause critical limb ischemia (CLI) res
Slide 6: Current Treatments and Limitations
Current Treatments and Limitations Non-Invasive Management Interventional Procedures Surgical Procedures Lifestyle Changes Often hard to sustain Pharmacotherapy Generally prescribed for life and do not treat the obstruction, making them ineffective for many More aggressive treatments often required
Slide 7: DABRA Technology and Mechanism of Action
DABRA Technology and Mechanism of Action DABRA Technology 308 nanometer excimer laser system Unique liquid-filled, full aperture ratio catheter High quality lumen Minimizes mechanical or thermal trauma Mechanism of Action Photoablation Removes blockages by breaking the bonds of the obstructing plaqu
Slide 8: Our Solution: DABRA
Our Solution: DABRA Portable Easy to store Intuitive interface Easy calibration Proprietary catheter Therapy Cost and Time Efficient Can cross and de-bulk wide variety of plaque Soft thrombus to hard calcified plaque Tool used by physicians to treat Chronic Total Occlusions (CTOs) prior to other alt
Slide 9: Clinically Demonstrated Solutions
9 Clinically Demonstrated Solutions Safety Record Pivotal Study 1 • Multi - site study at four sites in US and Mexico • Enrolled 64 patients with target blockage refractory to guidewire crossing Primary Efficacy Endpoint: • Successful crossing of target lesion based on angiographic analysis at time
Slide 10: Large US Addressable Market Opportunity
Large US Addressable Market Opportunity KEY DRIVER Current US Market Opportunity MARKET OPPORTUNITY Global Annual Total Addressable Market (TAM) Opportunity in 2017 $1.1B1 >17 Million PAD Sufferers in the US Coronary Artery Disease Other Vascular Occlusions In-Stent Restenosis Atherectomy (with a pr
Slide 11: Payors and Reimbursement
Payors and Reimbursement Approvals / Clearances DABRA: US FDA 510(k), CE Mark PHAROS: US FDA 510(k), CE Mark Payor Coverage Reimbursement claims for DABRA procedures typically submitted by providers to Medicare or other third-party payors using established Current Procedural Terminology (CPT) codes
Slide 12: Physician Practice Needs
Physician Practice Needs Ease of Use Established Safety and Efficacy Versatility Able to cross and debulk Economics We believe our solution expands provider economics
Slide 13: Pharos Excimer Laser Used to Treat Chronic Skin Diseases
Pharos Excimer Laser Used by Physicians to Treat Chronic Skin Diseases Psoriasis—chronic autoimmune disorder that causes cells to rapidly accumulate and affects the surface of the skin causing scales and red patches Vitiligo—autoimmune condition causing the skin to turn white due to the loss of pigm
Slide 14: Pharos Science, Advantages and Reimbursement
Pharos Science, Advantages and Reimbursement Pharos Science Same laser platform as DABRA 308-nanometer laser—the center of action spectrum for most immune-mediated inflammatory diseases Does not use heat or ablate lesions—treatments are generally painless Adjustable aiming beam accurately targets on
Slide 15: Fully Operational Manufacturing Facility
Fully Operational Manufacturing Facility Carlsbad, CA Sizable capacity for laser and catheter production 41,000 sq. ft. Carlsbad, CA with three controlled environments manufacturing facility fully staffed and operational Existing facility expected to be capable of manufacturing > 400 lasers/year and
Slide 16: Pipeline
Pipeline Indications (Not FDA Approved1) DABRA (Vascular) PHAROS (Dermatology) Atherectomy (IDE submitted) (with a pre-specified improvement in luminal patency) Cutaneous T-Cell Lymphoma (CTCL) Coronary Artery Disease (CAD) In-Stent Restenosis Other Vascular Occlusions No application has been made t
Slide 17: Intellectual Property Portfolio
Intellectual Property Portfolio Patents covering several aspects of the laser systems and delivery device The Company believes that its intellectual property comprises novel and useful inventions that can be protected by patents, and as such, has filed patent applications directed to innovative meth
Slide 18: Executive Team and Board of Directors
18 Executive Team and Board of Directors Will McGuire Chief Executive Officer Andrew Jackson Chief Financial Officer Jeffrey Kraws President Dan Horwood General Counsel and Secretary Martin Colombatto Chairman. Former VP and General Manager of Broadcom Maurice Buchbinder, MD Interventional Cardiolog
Slide 19: Financial Overview
Financial Overview Ra medical system [logo] Financial Overview
Slide 20: Business Model
Business Model Laser Module Capital Placement and Sale DABRATM Catheter Consumable Recurring Revenue Practical, easy to use equipment, anticipated recurring revenue single-use catheter solution
Slide 21: Results of Operations
Results of Operations ($ in thousands) Vascular Net Revenue Dermatology Net Revenue Total Net Revenue Gross Profit (Loss) Operating Expenses: Selling, General and Administrative (Incl. $0.9M and $20.4M stock comp exp.) Research and Development (Incl. $0.1M and $1.5M stock comp exp.) Total Operating
Slide 22: Financial Position
Financial Position ($ in thousands) Cash and Cash Equivalents and Short Term Investments Working Capital1 Total Assets Equipment Financing Accumulated Deficit Total Stockholders’ Equity As of Mar. 31, 2020 As of Dec. 31, 2019 $23,440 $30,577 $22,667 $29,186 $36,300 $44,081 $482 $558 $(124,858) $(117
Slide 23: Milestones
Milestones 3Q18 – IPO 1Q19 – Started Registry to study the benefit and safety profile of DABRA over a two-year term 2Q19 – Hired VP Quality, Regulatory and Clinical Affairs 3Q19 – Launched Pharos, Optimized 3Q19 – Received FDA approval for IDE to initiate atherectomy clinical trial 1Q20 – Enrolled f
Slide 24: Highlights
Highlights Novel Therapeutic Solution with Positive Clinical Study Results Existing US Reimbursement Structure Time Efficient and Easy-to-Use Solution Cost Benefits to Outpatient-Based Catheterization Laboratories $1.1B Targeted Global Annual TAM; >17.M PAD Sufferers in the US Single-Use Catheters H
Slide 25: Appendix
Appendix
Slide 26: Reconciliation of Net loss to Adjusted EBITDA
Reconciliation of Net loss to Adjusted EBITDA ($ in thousands) Statement of Operations Data: Net loss Depreciation and amortization Interest income Interest expense Income tax expense EBITDA Stock-based compensation Adjusted EBITDA Quarter Ended Mar. 31, 2020 Year Ended Dec. 31, 2019 $(7,701) $(56,9